ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PD-1/VEGF Bispecific Antibody

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 3, since Jul 28, 20261 company-led study, 1 open or runningNext primary completion: Dec 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical11 open or runningphase 3since Jul 28, 2026Jul 28, 2026Dec 2029phase 3 · NCT07739186

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2026First study: phase 3 study in Non-squamous Non-small Cell Lung CancerFirst studyNCT07739186 · 166 planned · China

Ahead

  1. Dec 2029Primary completion: phase 3 study in Non-squamous Non-small Cell Lung CancerNCT07739186

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07739186Non-squamous Non-small Cell Lung Cancer · China3RecruitingDec 2029166

How it is read

Names in the registry

  • “PD-1/VEGF Bispecific Antibody”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.